• John R Guyton, Harold E Bays, Scott M Grundy, Terry A Jacobson, and The National Lipid Association Statin Intolerance Panel.
• Division of Endocrinology, Diabetes, and Metabolism, Duke University Medical Center, 201 Trent Drive, Baker House 281, Durham, NC 27710, USA. Electronic address: john.guyton@duke.edu.
• J Clin Lipidol. 2014 May 1; 8 (3 Suppl): S72-81.

AbstractThis article from the National Lipid Association Statin Intolerance Panel provides a framework for understanding statin intolerance and makes general recommendations for health professionals. For specific guidance on adverse events related to muscle, liver, cognition, and glucose metabolism, one should refer to the other reports of the Statin Safety Task Force for those topics. Although statin adverse effects rarely lead to permanent sequelae, symptomatic intolerance frequently hinders cardiovascular risk reduction by statins. We emphasize here the advisory role of the clinician helping each patient to make personal decisions on statin tolerability. We identify a pressing need for further research on statin intolerance and make suggestions for research design. Copyright © 2014 National Lipid Association. Published by Elsevier Inc. All rights reserved.

12 keywords...

hide…